The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company sees the business reaching $100mn
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Subscribe To Our Newsletter & Stay Updated
